Sign in
Active, not recruitingEarly phase 1

Naltrexone Neuroimaging in Teens With Eating Disorders

Key facts

Who runs it
Children's Mercy Hospital Kansas City
Where
Kansas City, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Early phase 1
People taking part
60 people, planned
Started
17 Sept 2022
Expected to end
Jun 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Naltrexone
  • Placebo
Record updated
16 October 2026

Who can take part

Age
13 years to 21 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adolescents and young adults aged 13-21 years
  • Eating disorder diagnosis characterized by binge eating and/or purging (eg, Anorexia Nervosa-Binge/Purge, Bulimia Nervosa, Binge Eating Disorder, Other Specified Feeding/Eating Disorder) using Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria
  • Stable medication regimen (no dose or drug changes in the past 4 weeks)
  • Participant and parent/legal guardian (if under 18 years) are willing and able to provide informed permission/assent/consent for the study

Who cannot take part

  • Prior hypersensitivity reaction to naltrexone (e.g., anaphylaxis)
  • Pregnant (via UCG)
  • Non-removable metal in the body that is magnetic resonance imaging incompatible
  • Current naltrexone use
  • Self-reported opioid use in the past 7 days
  • A language barrier (e.g., non-English speaking) for the participant that precludes communication and/or ability to complete all study-related requirements

Where in United States

  • Children's Mercy Research InstituteKansas City, United States

About the trial

What the trial wants to find out

Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).

The 2 groups in the trial

  • Group ATreatment being tested

    All participants will receive both naltrexone and placebo, separated by a washout period, in a randomized, crossover fashion. Those randomized to group A will receive naltrexone then placebo. Those randomized to group B will receive placebo then naltrexone.

    Treatment: Naltrexone and Placebo

  • Group BTreatment being tested

    All participants will receive both naltrexone and placebo, separated by a washout period, in a randomized, crossover fashion. Those randomized to group A will receive naltrexone then placebo. Those randomized to group B will receive placebo then naltrexone.

    Treatment: Naltrexone and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders
Record updated
16 October 2026